Blog Posts - Daclatasvir Sofosbuvir



Daklinza(Daclatasvir): Bristol-Myers Lets Low-Income Countries Copy Hepatitis C Pills

Bristol-Myers Lets Low-Income Countries Copy Hepatitis C Pills Caroline Chen Bristol-Myers Squibb Co. has signed a broad agreement with Medicines Patent Pool, allowing the United Nations-backed... Monday HCV News Ticker- Hepatitis C: Coffee, Medicar...
by HCV New Drug Research on Nov 23, 2015

ALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class A or B)

97% of post-transplant patients with HCV genotype 1a achieved cure 91% of post-transplant patients with HCV genotype 3 achieved cure  No need seen to alter existing transplantation medication regimens Saturday, April 25, 2015 10:00 am EDT...
by Hepatitis C Research and News on Apr 25, 2015

All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study

Hepatology Volume 61, Issue 4 April 2015 Pages 1127–1135 David R. Nelson, James N. Cooper, Jacob P. Lalezari, Eric Lawitz, Paul J. Pockros, Norman Gitlin, Bradley F. Freilich, Ziad H. Younes, William Harlan, Reem Ghalib, Godson Oguchi, P...
by Hepatitis C Research and News on Apr 23, 2015

Janssen Highlights Hepatitis C Virus Development Programme at The International Liver Congress™ 2015 of the European Association for the Study of the Liver (EASL)

Presentations include late-breaking final results from the Phase 3 OPTIMIST trials and interim results from the Phase 2 IMPACT trial of simeprevir FOR IMMEDIATE RELEASE FOR MEDICAL AND TRADE MEDIA ONLY April 09, 2015 04:00 AM Eastern Daylight Time...

Medivir: Simeprevir, Sofosbuvir and Daclatasvir Phase II IMPACT Study Initiated to Treat Genotype 1 and 4 Hepatitis C Patients

Medivir: Phase II IMPACT Study Initiated to Evaluate Simeprevir in Combination with Sofosbuvir and Daclatasvir to Treat Genotype 1 and 4 Hepatitis C Patients  Medivir AB (STO:MVIR-B) today... Monday HCV News Ticker- Hepatitis C: Coffee, Medicar...
by HCV New Drug Research on Oct 10, 2014

Sofosbuvir for Hepatitis C: Simpler, Shorter, Safer?

William F. Balistreri, MD December 03, 2013 Aiming for the Ideal Strategy In 2011, the American Association for the Study of Liver Diseases (AASLD) issued an updated version of its practice guidelines for the treatment of chronic genotype 1 hepat...

The new era of hepatitis C treatment: still the tip of the iceberg?

European Review for Medical and Pharmacological Sciences 2013; 17: 2271-2274 A. GASBARRINI, F.R. PONZIANI, B.E. ANNICHIARICO, M. SICILIANO, A. CRAXÌ1 Gastroenterology Division, Catholic University of the Sacred Heart of Rome, School of Medicine, Rom...
by Hepatitis C Research and News on Oct 19, 2013

Hepatitis C Virus Infection: Looking for Interferon Free Regimens

The Scientific World JournalVolume 2013 (2013), Article ID 825375, 11 pageshttp://dx.doi.org/10.1155/2013/825375 Review Article J. González-Moreno and A. Payeras-Cifre Internal Medicine-Infectious Diseases Department, Hospital Son Llàtzer, Carreter...
by Hepatitis C Research and News on Oct 13, 2013


Trending Topics

Close